Cite
Boddu P, Borthakur G, Koneru M, et al. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018;8:369doi: 10.3389/fonc.2018.00369.
Boddu, P., Borthakur, G., Koneru, M., Huang, X., Naqvi, K., Wierda, W., Bose, P., Jabbour, E., Estrov, Z., Burger, J., Alvarado, Y., Deshmukh, A., Patel, A., Cavazos, A., Han, L., Cortes, J. E., Kantarjian, H., Andreeff, M., & Konopleva, M. (2018). Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in oncology, 8369. https://doi.org/10.3389/fonc.2018.00369
Boddu, Prajwal, et al. "Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia." Frontiers in oncology vol. 8 (2018): 369. doi: https://doi.org/10.3389/fonc.2018.00369
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018. PMID: 30319961; PMCID: PMC6167965.
Copy
Download .nbib